Diabetes, Obesity & Metabolism最新文献

{"title":"Integrative Proteomics-Metabolomics Profiling of Umbilical Cord Plasma With Machine Learning Reveals Candidate Biomarkers for Gestational Diabetes Mellitus.","authors":"Rui Zhao, Yidan Zhu, Yuanjie Liu, Zhaoqi Yuan, Haozheng Lu, Aimin Jiang, Tingting Chai, Meiying Guo, Cuiping Xu","doi":"10.1111/dom.71241","DOIUrl":"10.1111/dom.71241","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) is a common pregnancy complication, yet its molecular mechanisms remain incompletely understood. This study applied a multi-omics strategy combined with machine learning to identify candidate biomarkers and dysregulated molecular networks at the maternal-fetal interface.</p><p><strong>Methods: </strong>Umbilical cord plasma from 61 pregnant women, including 34 with GDM and 27 normoglycemic controls, was analysed using high-resolution proteomics and untargeted metabolomics. Hub candidate biomarkers were prioritised using LASSO, random forest and XGBoost; their discriminatory performance was assessed by ROC analysis and internally validated through bootstrap resampling and repeated cross-validation. Proteome-metabolome integration was performed with mixOmics. Immunohistochemistry (IHC) of placental tissues and RT-qPCR in HTR8/SVneo cells provided tissue-level and transcriptional validation, respectively.</p><p><strong>Results: </strong>Proteomics identified 37 differentially expressed proteins and selected five hub proteins-AFP, ORM1, PRSS2, LACRT and LCN1. The composite protein score demonstrated strong discriminatory performance, with an AUC of 0.984 (95% CI: 0.958-1.000). IHC confirmed the dysregulation of these hub proteins in GDM placentas and RT-qPCR revealed that the mRNA levels of AFP, ORM1 and PRSS2 were consistently upregulated under high-glucose conditions. Metabolomics identified 185 differential metabolites and three hub metabolites, including C₃₀H₃₈O₇, nicotine N-oxide and 7(1)-hydroxychlorophyll. The composite metabolite score showed an AUC of 0.991 (95% CI: 0.977-1.000). Cross-omics integration revealed an exploratory proteome-metabolome network associated with cornified envelope formation, keratinisation, humoral immunity and vitamin/nucleoside transport.</p><p><strong>Conclusions: </strong>Integrative proteomic-metabolomic profiling of umbilical cord plasma revealed coordinated immune, barrier and metabolic dysregulation in GDM, supporting exploratory multi-omics biomarker development and future mechanistic studies.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10261-10277"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variation in Treatment Patterns of Type 2 Diabetes in Older Patients.","authors":"Phuc Le, Ning Guo, Anita Misra-Hebert, Christopher B Boyer, Kevin M Pantalone, Hamlet Gasoyan, Nicholas J Casacchia, Michael B Rothberg","doi":"10.1111/dom.71178","DOIUrl":"10.1111/dom.71178","url":null,"abstract":"<p><strong>Aims: </strong>To estimate the proportion of older patients with type 2 diabetes (T2D) and HbA1c above or below goal at provider level and explore factors associated with patients being above or below goal.</p><p><strong>Materials and methods: </strong>We used 2023 Cleveland Clinic electronic health records, including patients ≥ 65 years old with T2D, ≥ 1 diabetes medication and ≥ 1 HbA1c measurement. Patients were assigned to their listed primary care provider or the one they saw most frequently and stratified into good, intermediate, or poor health. Outcomes were patients being above, at, and below goal, defined as HbA1c greater than, 0%-1.5% lower than, and ≥ 1.5% lower than goal, respectively. HbA1c goals were < 7.5% for patients with good, < 8% intermediate and < 9% poor health.</p><p><strong>Results: </strong>We included 406 providers and 15 865 patients. Across providers, 52.1% (range: 10%-87.9%) of patients were below goal (13.4% in those with good, 42.0% intermediate, 76.0% poor health); 11.3% (range: 0.0%-36.4%) were above goal (25.1% in those with good, 13.7% intermediate, 6.7% poor health). There was significant variation across providers (p < 0.001). In a multivariable model, having endocrinology providers (vs. internal medicine) decreased the adjusted relative risk ratio (aRRR) of being below goal (aRRR = 0.69; 95% CI: 0.57-0.82) and increased the probability of being above goal (aRRR = 1.65; 95% CI: 1.33-2.05).</p><p><strong>Conclusion: </strong>Substantial provider-level variation suggests that individualised glycemic management for older adults remains difficult to operationalise in routine care. Clinical decision support tools that automate assessment of health status and recommend glycemic goals may help clinicians better align glycemic management with patient needs.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10370-10378"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intramuscular Fat Assessed by AI-Assisted Muscle Ultrasound: Association With Cardiometabolic Risk Factors and Diabetic Nephropathy in Diabetes Mellitus.","authors":"Paloma Pérez-López, Juan José López-Gómez, Álvaro de la Calzada-Martínez, Jaime González-Gutiérrez, Beatriz Ramos-Bachiller, Esther Delgado-García, Emilia Gómez-Hoyos, Ana Ortolá-Buigues, Gonzalo Díaz-Soto, Rebeca Jiménez-Sahagún, Mario Alfredo Saavedra-Vásquez, Pablo Fernández-Velasco, Daniel De Luis-Román","doi":"10.1111/dom.71249","DOIUrl":"10.1111/dom.71249","url":null,"abstract":"<p><strong>Aims: </strong>Intramuscular fat (IMF) is increasingly recognized as a marker of ectopic adiposity and adverse cardiometabolic outcomes. Artificial intelligence (AI)-assisted ultrasound of the rectus femoris (RF) offers a non-invasive approach for quantifying IMF. This study evaluated the association of IMF with diabetes-related complications (particularly diabetic nephropathy) and metabolic risk factors in patients with diabetes mellitus (DM).</p><p><strong>Materials and methods: </strong>In this cross-sectional study, outpatients from a tertiary Endocrinology and Nutrition Department underwent anthropometric assessment, bioimpedance analysis, and muscular ultrasound. Ultrasound images were analysed using the PIIXMED AI-system (DAWAKO MedTech; Valencia, Spain) to quantify muscle (Mi) and fat (FATi) percentages (the latter indicating the IMF). Associations between IMF, clinical characteristics, metabolic biomarkers, and vascular complications were examined.</p><p><strong>Results: </strong>A total of 120 patients were included (57.5% men), with a mean age of 70.8 ± 10.3 years and diabetes duration of 13.8 ± 9.6 years. Most participants had type 2 DM (79.2%), with suboptimal glycaemic control (HbA1c 8.1% ± 1.5%). Individuals in the highest FATi quartile (> 43%) showed higher prevalence of microvascular complications, particularly diabetic nephropathy (44.0 vs. 14.7%, p = 0.001), and lower estimated glomerular filtration rate (63.6 ± 21.3 vs. 72.8 ± 20.1 mL/min/1.73m², p = 0.045). Multivariate analysis showed that FATi remained independently associated with nephropathy (OR 6.01, 95% CI 1.99-18.14; p < 0.01). ROC analysis identified a FATi threshold of 43.5% with modest discriminative ability (AUC = 0.668).</p><p><strong>Conclusions: </strong>AI-assisted ultrasound-derived FATi is associated with adverse metabolic profiles and diabetic nephropathy. Assessment of IMF may provide an accessible biomarker related to microvascular complications. Longitudinal and multicentre studies are needed to determine the role of IMF in diabetes-related complications.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10409-10417"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathway-Specific Polygenic Risk Score and Risk of Hyperglycaemic Progression in Patients With Type 2 Diabetes.","authors":"Sylvia Liu, Huili Zheng, Jia Le Ivan Tan, Keven Ang, Deqiang Zheng, Resham L Gurung, Su Chi Lim, Jian-Jun Liu","doi":"10.1111/dom.71294","DOIUrl":"10.1111/dom.71294","url":null,"abstract":"<p><strong>Aim: </strong>Pathway-specific polygenic risk scores (psPRS) provide insights into the heterogeneity of type 2 diabetes. We aim to study whether psPRS for beta cell dysfunction, obesity and metabolic syndrome associate with risk of hyperglycaemic progression in Southeast Asian patients with type 2 diabetes.</p><p><strong>Participants and methods: </strong>One thousand and fifty-nine insulin-naïve outpatients with type 2 diabetes were enrolled from a secondary hospital and a primary care facility. The psPRS were constructed as a weighted sum of risk alleles associated with specific metabolic pathways. Hyperglycaemic progression was defined as sustained insulin therapy lasting longer than 6 months.</p><p><strong>Results: </strong>During a median of 11.2 (8.9-11.8) years of follow-up, 188 participants initiated sustained insulin therapy. One SD increment in psPRS for metabolic syndrome was associated with a 17% increased risk for hyperglycaemic progression after adjustment for clinical risk factors (adjusted HR 1.17 [1.02-1.36]). Consistent results were obtained when hyperglycaemic progression was defined as a composite of sustained insulin therapy and requirement for insulin treatments (HbA1c > 8.5% with two or more non-insulin medications). Adding metabolic syndrome psPRS onto clinical risk predictors (diabetes onset age, HbA1c, HDL cholesterol, eGFR, urinary albumin-to-creatinine ratio) did not improve risk discrimination (delta AUC -0.01 [95% CI -0.02 to 0.01], p = 0.50). Neither psPRS for beta cell dysfunction nor obesity was associated with the risk of hyperglycaemic progression.</p><p><strong>Conclusion: </strong>psPRS for metabolic syndrome is nominally associated with risk of hyperglycaemic progression in multi-ancestry Southeast Asian people with type 2 diabetes. The psPRS does not provide incremental value for prediction of hyperglycaemic progression beyond clinical risk predictors.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10827-10834"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Association Between Diabetes and Osteoarthritis: A Population-Based Cohort Study.","authors":"Jianqiao Wang, Haonan Fang, Junjie Wang, Xusheng Cheng, Jingyi Yin, Xiaoyue Zhang, Xing Xing, Guoqi Cai","doi":"10.1111/dom.71286","DOIUrl":"10.1111/dom.71286","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (DM) and osteoarthritis (OA) frequently coexist in middle-aged and older adults, but their longitudinal associations are mixed. This study aimed to investigate the bidirectional associations of DM with knee and hand OA (KOA and HOA) in a large population-based cohort of middle-aged and older adults.</p><p><strong>Methods: </strong>This study utilized data from the UK Biobank. The presence and incidence of DM and OA were ascertained by participant self-reports, inpatient hospital records, primary care and death records. The associations between baseline DM and the incidence of KOA and HOA, as well as baseline KOA and HOA and the incidence of DM, were evaluated using accelerated failure time models because the proportional hazards assumption was violated.</p><p><strong>Results: </strong>Among participants without KOA and HOA at baseline, baseline DM was significantly associated with earlier onset of KOA but not HOA before BMI adjustment (time ratio [TR] = 0.91, 95% confidence interval [CI] 0.87-0.95, p < 0.001), while further adjusting for BMI showed a marginal association between DM and delayed KOA onset (TR = 1.04, 95% CI: 1.00-1.09, p = 0.058) during the 13.5-year follow-up. Among participants without DM at baseline, both prevalent KOA and HOA were associated with earlier DM onset (KOA: TR = 0.91, 95% CI: 0.86-0.97, p = 0.005; HOA: TR = 0.68, 95% CI: 0.50-0.95, p = 0.021), before or after adjusting for BMI.</p><p><strong>Conclusion: </strong>Our findings reveal an asymmetric bidirectional link between DM and joint-specific OA. While both KOA and HOA are associated with earlier DM onset, the impact of DM on KOA is confounded or mediated by BMI, where covariate adjustment induces directional instability.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10565-10573"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-In-Human Study of Mirogabalin (BM2216) Sustained-Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants.","authors":"Peiyang Song, Hongtao Zhao, Mingxue Zhu, Lei Wan, Yuan Chen, Zhongping Li, Chengyong Tang","doi":"10.1111/dom.71284","DOIUrl":"10.1111/dom.71284","url":null,"abstract":"<p><strong>Aim: </strong>To characterise the pharmacokinetics (PKs) and safety of BM2216 sustained-release (SR) tablets after single-dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple-dose PK of BM2216 SR tablets with mirogabalin besylate tablets to estimate the bioavailability.</p><p><strong>Materials and methods: </strong>This was a single-centre, randomised, open-label, phase I study conducted in healthy adult participants aged 18-45 years old, consisting of three parts: Part 1 (Food effect and single-dose PK comparison): 18 participants were 1:1:1 randomised into three sequences: (1) 16.5 mg BM2216 (fasting 18:00, QD); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next-day 6:00, 7.5 mg/dose); (3) 16.5 mg BM2216 (post-high-fat dinner, QD). A 3-period crossover design with a 72 h washout period; Part 2 (Single-dose proportionality): 32 participants were equally assigned to four groups, receiving BM2216 SR tablets (5.5, 11, 16.5, or 33 mg) 30 min post-standard meal, respectively; Part 3 (Multiple-dose PK comparison): 16 participants were 1:1 randomised into two sequences: (1) BM2216 (post-dinner, 16.5 mg QD, four consecutive days); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next-day 6:00, 7.5 mg/dose, four consecutive days). Crossover was conducted with a 72 h washout period. PK parameters were calculated and compared using non-compartmental analysis.</p><p><strong>Results: </strong>The most common adverse events (AEs) were dizziness (15.6%), increased bile acids (12.5%) and vertigo (12.5%). Dizziness appeared in both the 16.5 and 33 mg dose groups, while vertigo was only seen in the 33 mg group, no serious AEs occurred. Single postprandial doses (5.5-33 mg) exhibited linear PKs: T _max median 3.00-5.02 h, with dose-proportional increases in C _max, AUC_0-t and AUC_0-∞. Multiple doses (16.5 mg QD, 4 days) had T _max,_ss median 5.996 h, t _1/2,ss mean 3.8075 h; The RAC_,Cmax and RAC_,AUC were 0.9965 and 1.0150, indicating no accumulation; high-fat meal significantly extending T _1/2 by 3.5 h, increasing C _max by 16%, delaying T _max by 3 h and raising AUC by 30%. Postprandial BM2216 (16.5 mg) and fasting mirogabalin besylate (15 mg) had equivalent mirogabalin AUC; BM2216 showed good sustained-release properties.</p><p><strong>Conclusions: </strong>BM2216 SR was safe and shows linear PK (5.5-3 mg single dose). Due to significant food effect and comparable QD exposure to the reference drug, postprandial QD administration is recommended. These data support further efficacy trials in neuropathic pain patients.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10795-10813"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits.","authors":"Mandana Chitsazan, Juhi K Parekh, Amanda L Grundmann, Emily S Lau, Mona Alotaibi, Bing Yu, Casey M Rebholz, Elizabeth Selvin, Norrina B Allen, Matthew A Allison, Mohit Jain, Susan Cheng, Jennifer E Ho","doi":"10.1111/dom.71269","DOIUrl":"10.1111/dom.71269","url":null,"abstract":"<p><strong>Aims: </strong>The molecular pathways by which obesity contributes to systemic inflammation are unclear. Eicosanoids are bioactive lipids that govern the upstream initiation of pro- and anti-inflammatory activity. We sought to investigate the association of eicosanoids with obesity, adiposity, and cardiometabolic traits.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) study with external validation in two community-based cohorts: Framingham Heart Study and Atherosclerosis Risk in Communities Study. We measured 811 eicosanoids using a directed, non-targeted mass spectrometry-based platform and examined their associations with BMI and eight related adiposity and cardiometabolic traits using multivariable-adjusted linear regression.</p><p><strong>Results: </strong>Among 5101 MESA participants (mean age 63 years, 53% women), we found 255 eicosanoids and related metabolites associated with BMI (FDR q < 0.01 for all). Among these, 82 showed consistent associations across all three cohorts, including 18 metabolites with known identities: 9 were associated with lower BMI including docosahexaenoic acid derivative 19,20-DiHDPA, arachidonic acid derivatives (20-carboxy-arachidonic acid, 5,6-diHETrE, 14,15-diHETrE, 15-HpETE), and eicosapentaenoic acid derivative 5-HpEPE. By contrast, 9 metabolites associated with higher BMI including hydroxyoctadecenoic acid (HOME), 11-hydroxy-9-octadecenoic acid (11-HOME), and adrenic acid. Many BMI-associated metabolites overlapped with other adipose traits including 240 (94%) with waist circumference and 93 (36%) with visceral adipose tissue.</p><p><strong>Conclusion: </strong>We identified 82 BMI-associated eicosanoids, including docosanoids and arachidonic acid derivatives associated with lower BMI, while octadecanoids and adrenic acid derivatives were associated with higher BMI. Our findings highlight the role of bioactive lipids and specific pro- and anti-inflammatory pathways that may underlie adverse cardiometabolic consequences of obesity.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10696-10708"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13600765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic Renal Health Profile, Intensive Blood Pressure-Lowering Treatment and Cognitive Dysfunction: A Post Hoc Analysis of the SPRINT Trial.","authors":"Siyu Wang, Kan Wang, Zhiping Tan, Xiaoyun Zhang, Yu Xiang, Xuan Zhao, Yueyue Wang, Xi Meng, Tiange Wang, Zhiyun Zhao, Mian Li, Jie Zheng, Min Xu, Jieli Lu, Yufang Bi, Yu Xu","doi":"10.1111/dom.71217","DOIUrl":"10.1111/dom.71217","url":null,"abstract":"<p><strong>Background: </strong>Whether participants with different cardiometabolic renal health profiles would derive comparable cognitive benefits from intensive blood pressure (BP)-lowering treatment remains underexplored.</p><p><strong>Methods: </strong>This post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) derived a cardiometabolic renal health profile based on baseline levels of fasting plasma glucose, non-high-density lipoprotein cholesterol, estimated glomerular filtration rate, urine albumin-to-creatinine ratio and history of subclinical and clinical cardiovascular disease. Participants were categorised into tertiles (favourable, intermediate and poor) based on the distribution of the risk-weighted profile. Cognitive outcomes included probable dementia, mild cognitive impairment (MCI) and a composite of the two.</p><p><strong>Results: </strong>A total of 8162 participants (mean age 67.8 years; 35.2% women) with complete baseline profile data were included. In exploratory tertile-based analyses, intensive BP-lowering treatment was associated with a lower risk of MCI among participants with favourable profiles (adjusted HR 0.64, 95% CI 0.48-0.86), with the largest absolute risk difference observed in this group (adjusted ARD, -3.05%; 95% CI, -4.85% to -1.24%) and a significant interaction on the ARD scale (p for interaction = 0.039). No interaction was observed for the other cognitive outcomes or adverse events.</p><p><strong>Conclusions: </strong>Intensive BP-lowering treatment tended to be associated with greater absolute risk reductions for MCI among participants with favourable cardiometabolic renal health profiles. These findings should be considered exploratory and require validation in future studies.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT01206062.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10058-10069"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment.","authors":"Mahip Acharya, Deboleena Thakur","doi":"10.1111/dom.71199","DOIUrl":"10.1111/dom.71199","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10867-10877"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Impact of 2026 ACC/AHA PREVENT-ASCVD Risk Thresholds on Statin Eligibility in U.S. Adults.","authors":"Sahil Ghay, Baneet Kaur, Daniela Urina-Jassir, Francine K Welty, Tarec K Elajami","doi":"10.1111/dom.71228","DOIUrl":"10.1111/dom.71228","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10882-10885"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}